Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

Science News

Parkinson’s Foundation researchers and other scientists worldwide make continual advances in understanding Parkinson’s disease (PD) with revolutionary research. We monitor it all in our effort to improving care and advance research toward a cure. Browse our collection here:

Regular Exercise Has Long-Term Benefits in Parkinson’s
Friday, June 16, 2017

A new study finds that people with Parkinson's disease (PD) who regularly exercised two and a half hours per week had an improved quality of life and mobility over two years compared to people who did not exercise or who exercised less. Furthermore, people with more advanced PD benefitted the most from regular exercise. The results appear in the March edition of the Journal of Parkinson’s Disease.

Drug Targeting Toxic Alpha-Synuclein Is Found Safe in Early Clinical Trial
Friday, June 16, 2017

In an early, small clinical trial an experimental drug designed to clear away a toxic protein associated with Parkinson’s disease (PD) was found to be safe in people. This result is a step toward evaluating whether therapies that target the alpha-synuclein protein can slow PD progression.  The research appears in the February edition of Movement Disorders.

Low-Fat Dairy Foods Associated with Modest Increased Risk of Parkinson’s
Wednesday, June 7, 2017

Frequently consuming dairy foods, in particular low-fat milk, is associated with a modest increased risk of developing Parkinson’s disease (PD), according to a new study published in the June 7 online edition of Neurology. However, the results do not demonstrate that dairy products cause Parkinson’s, and the risk of developing the disease for anyone remains low.

Lifespan in Parkinson's Nearly Identical to General Population
Wednesday, May 17, 2017

A new study finds that, overall, lifespan for those living with Parkinson’s disease (PD) is nearly identical to those in the general population. The study looked at a group of diseases called synucleinopathies, including Parkinson’s.  The results appear in the May 15 online edition of JAMA Neurology.

New Evidence Suggests That Parkinson’s Begins in the Gut
Wednesday, April 26, 2017

According to new research, people who had surgery to cut the main nerve connecting the brain with the stomach, a longstanding treatment for ulcers, had a trend of a lower risk of developing Parkinson’s disease (PD). Published in the April 26 online edition of Neurology, this result adds weight to the hypothesis that PD may begin in the gut and travel to the brain.

FDA Allows Marketing of a Genetic Test for Medical Conditions Including Parkinson’s
Thursday, April 6, 2017

Earlier today, the US Food and Drug Administration (FDA) announced that it will allow direct marketing to consumers of a genetic test that identifies predispositions for 10 medical conditions, including Parkinson’s. Such tests are referred to as direct-to-consumer or DTC.

Potential Parkinson’s Therapy Harnesses Immune System Cells
Monday, April 3, 2017

Researchers have found the drug sargramostim, currently used to boost the immune systems of people undergoing chemotherapy, to be relatively safe in people with Parkinson’s disease (PD). This result opens the door to testing its ability to protect the brain cells affected by PD. The results of this small, phase I clinical trial appear in the March 23 online edition of npj | Parkinson’s Disease.

Hepatitis B and C May Increase Parkinson’s Risk
Wednesday, March 29, 2017

Infections with the viruses that cause hepatitis B and hepatitis C are associated with increased rates of Parkinson’s disease (PD), according to a study published in the March 29 online edition of Neurology. More research is needed to explain this connection.

FDA Approves Safinamide (Xadago®) as an Add-on Treatment for Parkinson’s
Wednesday, March 22, 2017

The Parkinson’s Foundation alerts the community that the US Food and Drug Administration (FDA) has approved safinamide tablets (Xadago®) as an add-on treatment for people with Parkinson’s who are currently taking carbidopa/levodopa and experiencing “off” episodes. The FDA announced the approval on March 21.

Light Therapy May Promote Daytime Alertness and Better Sleep in Parkinson's
Sunday, March 19, 2017

In a new study, when people with Parkinson’s disease (PD) who experienced daytime excessive sleepiness were exposed to bright light twice a day, using light boxes similar to those available in drug stores, they were more alert in the daytime and slept better at night. This research funded by the Parkinson’s Foundation appears in the February 20 online edition of JAMA Neurology.

Pages

mail icon

Subscribe to get the latest news on treatments, research and other updates.